BUSINESSFRANCE 24
US launches Germany pharma pricing probe, raising threat of new tariffs
The United States has launched an investigation into Germany's pharmaceutical pricing policies, which could lead to new tariffs. The probe, under Section 301 trade authorities, examines whether Germany's practices underpay for innovative medicines and harm US commerce.
Mentioned
Related Signal
Adjacent reporting
- US launches trade investigation into Germany’s spending on new medicines
- US probes Germany's 'persistent underpayment' for drugs
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
- STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
- STAT+: Trump’s drug-pricing deals set to be tested by new product launches
- Trump administration announces new tariffs on drugmakers